A Phase 2, Single-center, Open-label, Randomized, Comparator-controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Subjects With Osteomyelitis Known or Suspected to be Due to Gram- Positive Organisms

Trial Profile

A Phase 2, Single-center, Open-label, Randomized, Comparator-controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Subjects With Osteomyelitis Known or Suspected to be Due to Gram- Positive Organisms

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2018

At a glance

  • Drugs Dalbavancin (Primary)
  • Indications Osteomyelitis
  • Focus Therapeutic Use
  • Sponsors Durata Therapeutics
  • Most Recent Events

    • 24 Apr 2018 Interim results (Data cut off: 17 Nov, 2017) with follow-up at 6 months and 1 year from this study, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases.
    • 21 Feb 2018 Status changed to completed.
    • 06 Aug 2017 Planned End Date changed from 1 Nov 2017 to 23 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top